HDAC9 and non-small cell lung carcinoma: This has been demonstrated in non-small cell lung cancer and glioblastoma cells, where HDAC inhibition increases SP1 acetylation, reduces its binding to target promoters, and suppresses downstream gene expression [38, 39].